1	2	3	4	5
5	M/s. Franco Indian Pharmaceuticals	14·02	0·43	13·59
6	M/s. Pfizer Ltd.	87·61	19·90	67·71
7	M/s. Anil Starch Products	11·61	Nil	11·61
8	M/s. S. G. Pharmaceuticals	205·36	Nil	205·36
9	M/s. Tamilnadu Dadha Pharmaceuticals	37·97	Nil	37·97
10	M/s.Merind Ltd.	781·58	Nil	781·58
11	M/s. Glaxo Labs.	7178·18	819·00	6359·13
		11560·52	1306·62	10253·90

Fixation of Prices of Bulk Drugs and their Formulation

657. SHRI MOHD. KHALEELUR RAHAMAN: Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 402 given in the Rajya Sabha on the 31st December, 1990 and state:

(a) whether it is a fact that there are certain drugs which are imported as well as indigenously produced;

(b) what are the names of these drugs and on what basis their formulation are fixed;

(c) what is the indigenous price and landed cost of import of each;

(d) whether it is a fact that formulations based on Sulphamoxole, Zinc Bacitiracin Ethisterone Novgestrol, Polymixio 'B' Sulphate and Thioridazine are being sold at very high prices;

(e) what is the bulk drug price taken for fixation of the formulation prices; and

(f) by when the prices of bulk drugs would be fixed?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIAMENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) Yes, Sir.

(b) and (c) The requisite information to the extent available would be collected and will be laid on the Table of the House.

(d) All these bulk drugs have been brought under price control under Category II of DPCO, 1987. The prices of formulations based on Sulphamaxole, Zinc Bactitracin, Polymixin 'B' Sulphate and Thioridazine have already been fixed in accordance with the provisions contained in the DPCO, 1987. BICP has been requested to workout the prices of formulations based on Ethisterone and Novgestrol on *suo moto* basis.

(e) The requisite information is as under:—

S. No.	Name of the Product	Price taken
1	Sulphamoxole	Rs. 430·00 per kg.
2	Zinc Bacitractin	Rs. 203·10 per MU
3	Polymixin 'B' Sulphate	Rs. 13·72 per MU
4	Thioridazine	Rs. 6922·08 per kg.

(f) BICP is already on the job.

Justification for Allowing Incidentals to Fixation of Formulation Prices

658. SHRI MOHD. KHALEELUR RAHMAN: Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 1168 given in Rajya Sabha on 7th January, 1991 and state:

(a) what are the names of two or three formulators for whom ceiling prices were announced in respect of Pilocarpine, Prednisolone and Trimethoprim plus Sulphadizine;

(b) whether it is a fact that drug industry is siphoning off its profits by giving discounts, incentives and distribution of gifts;

(c) what were the expenses on this account of five major companies during the last one year; and

(d) what is the justification for allowing 20 per cent discounts over and above the trade commission and also allowing 8 per cent incidentals?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIAMENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) The requisite information to the extent available is given in the annexed statement.

(b) to (d) While fixing the prices of controlled formulations, a fixed Maximum Allowable Post-Manufacturing Expenses (MAPE), which is 75 per cent and 100 per cent in the case of Category I and Category II formulations respectively, is allowed. The manufacturers are required to meet their expenses including giving discounts, incentives, etc. within the given MAPE. Incidentals within a limit of 8 per cent are allowed to cover Sales Tax, Octroi, Insurance, Freight etc.

Statement

Sl. No.	Name of the bulk drug	Name of the formulator
1	Pilocarpine	(1) Fair-deal Corporation
		(2) Bell Labs.
2	Prednisolone	(1) Wyeth Labs.
		(2) Hoechst
		(3) Pifzer
3	Trimethoprim+Sulphadizaine	(1) Hindustan Ciba Geigy
		(2) Astra IDL
		(3) Etinor